Vicente Torres Fernández

Vicente Torres Fernández has a diverse work experience spanning various roles and companies. Vicente is currently working at Neuraxpharm as the Global Head of Corporate Multiple Sclerosis Business Unit. Vicente'sresponsibilities include overseeing the commercialization of BRIUMVI® and setting the vision and strategy for the successful launch of innovative MS products.

Prior to their current role, Vicente worked at Biogen where they held several positions including Executive Director/Head of Multiple Sclerosis & Cross TA Congress Management, Senior Director/Global Product Development and Commercialization Lead MS Fumarates, Commercial Director Neurosciences, and Business Unit Director Multiple Sclerosis.

Vicente also worked at CESIF as the Director of the Master's in health biotechnology program and contributed to the outstanding performance of CESIF Business School. In addition, they have experience working at AbbVie, Sandoz, Eli Lilly, Disaplast S.L, and PUPILS ENGLISH SCHOOL (ACTIL S.L) in various sales and management roles.

Throughout their career, Vicente has demonstrated strong leadership skills, strategic planning abilities, and a deep understanding of the pharmaceutical industry, particularly in the field of neurosciences and immunology.

Vicente Torres Fernández completed an Executive Marketing Excellence Program at IE Business School in 2014. In the same year, they also pursued a Master's Degree in "PROGRAMA DE DESARROLLO Leading the future management program" at Universidad CEU San Pablo. In 2007, they obtained a Master of Business Administration (M.B.A.) degree from IE Business School. Earlier, they completed a Chesmitry Degree at Universidad de Murcia from 1991 to 1996. Vicente also attended a Management Development Program at Babson College in 2019 and pursued a Collaborator & Advisor role in Empresa, gestión, marketing y disciplinas afines at IMF Smart Education from 2016 to 2019. Additionally, they acquired a Master's Degree in ENGLISH FOR PHARMABUSINESS from British Council/EPHOS in 2008.